Abdominal aortic aneurysm is a life-threatening condition that often remains silent until rupture, and clinical management relies largely on aneurysm diameter. While traditional risk factors such as smoking and age are well established, the evidence on comorbidities, medications, biomarkers, and biomechanical parameters has remained fragmented. To address this gap, researchers conducted the first umbrella meta-analysis to integrate evidence across all major domains of AAA risk and protective factors. Following PRISMA 2020 guidelines, the team screened 2,081 records from PubMed and Embase and included 36 non-overlapping systematic reviews and meta-analyses, covering 49 exposure–outcome associations across 39 distinct factors related to AAA presence, growth, and rupture, with methodological quality appraised by AMSTAR-2 and evidence certainty graded by the GRADE system.
Several factors stood out with consistent protective signals. Diabetes was associated with lower AAA presence (OR 0.57), slower aneurysm growth (−0.25 mm/year), and lower rupture risk (OR 0.71). Statin use was linked to reduced aneurysm growth and a lower rupture risk (OR 0.63), supported by moderate-quality evidence, while metformin use was associated with slower aneurysm expansion. On the lifestyle side, higher physical activity was associated with reduced AAA presence, whereas obesity showed a positive association.
On the risk side, hypertension increased AAA incidence (RR 1.66). Among circulating biomarkers, D-dimer, fibrinogen, and hsCRP were positively associated with AAA presence, alongside elevations in IL-6, MMP-9, and the thrombin–antithrombin complex. Comorbidities including COPD, coronary artery disease, simple renal cysts, and primary abdominal wall hernia were also associated with higher AAA presence. In contrast, ARBs, beta-blockers, antiplatelet agents, and antibiotics showed no significant associations—and doxycycline, rather than being protective, was associated with a small increase in aneurysm growth. Biomechanically, the peak wall rupture index (PWRI) was positively associated with rupture risk.
The analysis confirms the multifactorial nature of AAA and establishes a clear evidence hierarchy—but it also shows that most factors lack high-quality evidence, and observational associations cannot establish causality. The authors offer conservative implications: statin therapy should follow established cardiovascular prevention indications in patients with AAA, metformin use in non-diabetic individuals remains investigational, and antibiotics are not recommended for AAA-specific risk management outside clinical trials. Standardized measurement and prospective studies are needed to improve risk prediction and therapeutic strategies.
The work titled “Associations of Comorbidities, Medications, Biomarkers, and Hemodynamic Factors with Abdominal Aortic Aneurysm Outcomes: An Umbrella Meta-Analysis” was published in Vascular Research (published on April 10, 2026).
DOI:10.15302/VR.2025.0007